Ultrasensitive next‐generation sequencing–based detection of circulating human papillomavirus DNA for cervical cancer recurrence monitoring
Cancer · 2026
DOI: 10.1002/cncr.70282 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Sara Bønløkke und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Neoplasm Recurrence, Local, DNA, Viral, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: KV Fonden, Søster og Verner Lipperts fond, IMK Almene Fond.
Abstract (Originalsprache)
Background
Circulating cell‐free human papillomavirus (ccfHPV) DNA is a promising biomarker for cervical cancer monitoring. This study used next‐generation sequencing (NGS) to assess its prognostic and surveillance value.
Methods
The authors included 141 cervical cancer patients (International Federation of Gynecology and Obstetrics IA1–IVB) grouped by treatment: primary surgery ( n = 50), primary surgery + adjuvant oncological ( n = 22), and primary oncological treatment ( n = 69). Plasma was collected pretreatment, at early follow‐up (first post‐treatment sample [FPS]), and during longer follow‐up. ccfHPV DNA was detected using an NGS‐based assay, enabling high sensitivity without prior knowledge of human papillomavirus (HPV) genotype. Associations between ccfHPV DNA status and recurrence were assessed using Cox proportional hazards models, and predictive accuracy was evaluated via sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).
Results
Pretreatment ccfHPV DNA positivity was detected in 8.0%, 36.4%, and 82.6% of patients across the groups, and ccfHPV DNA positivity was significantly associated with higher recurrence risk (adjusted hazard ratio [HR], 4.92; 95% confidence interval [CI], 1.29–18.7; p = .02). At FPS, ccfHPV DNA positivity strongly predicted recurrence (adjusted HR, 19.1; 95% CI, 7.27–50.2), with a PPV of 83% and NPV of 90% for recurrence within 50 months. Among patients who developed recurrence, ccfHPV DNA was detectable before clinical evidence of recurrence in 60.9% of cases with a mean lead time of 144 days. Conclusion ccfHPV DNA detected by NGS is a strong prognostic biomarker for residual disease or recurrence. Its strong performance, already at early follow‐up, supports its integration into individualized follow‐up strategies. Prospective multicenter studies should validate these findings and guide clinical implementation. Trial Registration The study was registered with ClinicalTrials.gov (identifiers: NCT03749720)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Department of Obstetrics and Gynecology, Gødstrup Regional Hospital, Herning, Denmark.
- Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
- Department of Public Health, Unit for Biostatistics, Aarhus University, Aarhus, Denmark.
- Department of Oncology, Odense University Hospital, Odense C, Denmark.
ORCID-Profile: Sara Bønløkke
Förderung
- KV Fonden
- Søster og Verner Lipperts fond
- IMK Almene Fond
- Civilingeniør Frode V. Nyegaard og Hustrus Fond
- Fabrikant Einar Willumsens Mindelegat
- Folketingsmand J. Christensen og hustru K. Christensens Fond
- Grosserer A.V. Lykfeldt og Hustrus Legat
- Harboefonden
Zitieren
APA
Bønløkke, S., Stougaard, M., Sorensen, B. S., Parner, E., Nyvang, G. B., Lindegaard, J. C., Blaakær, J., Bertelsen, J., Fuglsang, K., & Steiniche, T. (2026). Ultrasensitive next‐generation sequencing–based detection of circulating human papillomavirus DNA for cervical cancer recurrence monitoring. Cancer. https://doi.org/10.1002/cncr.70282
Vancouver
Bønløkke S, Stougaard M, Sorensen BS, Parner E, Nyvang GB, Lindegaard JC, et al. Ultrasensitive next‐generation sequencing–based detection of circulating human papillomavirus DNA for cervical cancer recurrence monitoring. Cancer. 2026. doi:10.1002/cncr.70282
BibTeX
@article{Bnlkke2026,
author = {Bønløkke, Sara and Stougaard, Magnus and Sorensen, Boe Sandahl and Parner, Erik and Nyvang, Gitte-Bettina and Lindegaard, Jacob Christian and Blaakær, Jan and Bertelsen, Jesper and Fuglsang, Katrine and Steiniche, Torben},
title = {Ultrasensitive next‐generation sequencing–based detection of circulating human papillomavirus DNA for cervical cancer recurrence monitoring},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70282}
}
EUVIMED